20 articles
Researchers identify four LSC subtypes that predict venetoclax resistance and reveal matched subtype-specific therapies for AML patients.
A new review reframes how myeloid cells fuel or fight tumors, pointing to plasticity — not just cell diversity — as the core therapeutic target.
A first-in-human trial shows CAR-modified stem cell memory T cells outperform standard CAR T cells in expansion, persistence, and complete responses.
New research reveals how a specific protein causes anemia in myelodysplastic syndromes and predicts treatment response.
Chinese researchers developed a breakthrough method to mass-produce powerful immune cells that hunt and destroy cancer tumors.
New research reveals how lung cancer subclones develop distinct immune evasion strategies, complicating immunotherapy response.
New research reveals how B cell lymphomas disrupt immune system organization through chemokine manipulation.
Engineered immune cells target CD19+ cancer cells in patients with treatment-resistant lymphoma and leukemia.
A sweeping review of CAR-T and CAR-NK cell therapies in acute myeloid leukemia, covering clinical trial outcomes, key targets, and next-gen strategies.
Scientists identify a mitochondria-proteasome-haem pathway that silences immune cells — and show bortezomib can fix it in CAR-T therapy.
A 13-modality molecular analysis of 173 AML patients reveals distinct subtypes, metabolic reprogramming, and a machine-learning-validated therapy target.
New research reveals how tumors reprogram neutrophils to produce CCL3, turning immune defenders into cancer allies.
Researchers modified children's own immune cells to fight B-cell leukemia and lymphoma when standard treatments failed.
A landmark WGS study of 1,804 myeloid neoplasia patients uncovers how telomere length varies by mutation type and cancer subtype.
BCG therapy for bladder cancer travels to bone marrow, reprogramming stem cells to produce enhanced immune cells that fight tumors throughout the body.
AML stem cells produce BHB via autonomous ketogenesis to block ferroptosis, revealing a targetable metabolic vulnerability in leukemia.
A landmark Cell study reveals that the patient's own immune system—not just CAR T cells—decides outcomes in recurrent glioblastoma.
Australian biotech company creates targeted treatment that attacks malignant plasma cells while sparing healthy ones in multiple myeloma patients.
Multi-omics study reveals exhausted T-cells in CLL lymph nodes and identifies galectin-9 as a promising therapeutic target for overcoming immune evasion.
New molecular analysis tool could revolutionize treatment decisions for chronic myelomonocytic leukemia patients.
